Lexicon Pharmaceuticals Missed Q1 Estimates, Top Line Down 64%

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a Q1 loss of $0.09 per share, wider than consensus estimates for a loss of $0.07 per share. Revenues fell 64% year-over-year to $0.6 million, missing consensus estimates of just over $1 million. According to the company, Lexicon's first-in-class drugs continue to make significant progress. Lexicon Pharmaceuticals has a potential upside of 48.8% based on a current price of $1.68 and an average consensus analyst price target of $2.5.

Category:

News & Politics

Tags:

• Lexicon Pharmaceuticals
• LXRX
• Earnings
• EPS
• Finance
• Investing
• Stock
• Trading
• News
• Analysis